TNBC constitutes around 12-17% of breast cancers (70), and is notorious for its aggressiveness, which results in late-stage diagnosis (sometimes with metastasis), as well as its difficulty of treatment, due to its ER-, PR- and HR-negative nature that rules out utility of classical receptor-targeting therapies. This evidence concerns the gene PGR and breast cancer.